Tiziana Life Sciences Ltd Com Financials

TLSA

Source SEC Filings (10-K/10-Q) Updated Dec 31, 2024 Currency USD FYE December

This page shows Tiziana Life Sciences Ltd Com (TLSA) financial statements, including the income statement, balance sheet, cash flow statement, and key financial ratios. View 9 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Financial Health Signals

Piotroski F-Score Weak

3/9

Tiziana Life Sciences Ltd Com passes 3 of 9 financial strength tests. 2 of 4 profitability signals pass, 1 of 3 leverage/liquidity signals pass.

Earnings Quality Low Quality

0.13x

For every $1 of reported earnings, Tiziana Life Sciences Ltd Com generates $0.13 in operating cash flow (-$1.5M OCF vs -$11.9M net income). This low ratio suggests earnings are primarily driven by accounting accruals rather than cash generation, which may not be sustainable.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

N/A

EBITDA

N/A

Net Income

-$11.9M

YoY+32.9%

Tiziana Life Sciences Ltd Com reported -$11.9M in net income in fiscal year 2024. This represents an increase of 32.9% from the prior year.

EPS (Diluted)

N/A

Cash & Balance Sheet

Free Cash Flow

-$1.5M

Tiziana Life Sciences Ltd Com generated -$1.5M in free cash flow in fiscal year 2024, representing cash available after capex.

Cash & Debt

$3.7M

YoY+214.8%

5Y CAGR+79.5%

Tiziana Life Sciences Ltd Com held $3.7M in cash against $0 in long-term debt as of fiscal year 2024.

Dividends Per Share

N/A

Shares Outstanding

111M

YoY+8.1%

5Y CAGR-4.0%

Tiziana Life Sciences Ltd Com had 111M shares outstanding in fiscal year 2024. This represents an increase of 8.1% from the prior year.

Margins & Returns

Gross Margin

N/A

Operating Margin

N/A

Net Margin

N/A

Return on Equity

-301.4%

YoY+18.2pp

5Y CAGR-288.0pp

Tiziana Life Sciences Ltd Com's ROE was -301.4% in fiscal year 2024, measuring profit generated per dollar of shareholder equity. This is up 18.2 percentage points from the prior year.

Capital Allocation

R&D Spending

N/A

Share Buybacks

N/A

Capital Expenditures

$19K

5Y CAGR+36.6%

Tiziana Life Sciences Ltd Com invested $19K in capex in fiscal year 2024, funding long-term assets and infrastructure.

TLSA Income Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	$6K-40.0%	$10K+42.9%	$7K-46.2%	$13K-23.5%	$17K-45.2%	$31K
Income Tax	-$4.9M-1187.5%	$449K	N/A	-$3.2M-46.8%	-$2.2M0.0%	-$2.2M
Net Income	-$11.9M+32.9%	-$17.7M-14.9%	-$15.4M+34.2%	-$23.4M+10.4%	-$26.1M-180.3%	-$9.3M
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'24	Q4'23	Q4'22	Q4'21	Q4'20	Q4'19	Q4'18	Q4'17
Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Cost of Revenue	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
SG&A Expenses	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Income Tax	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
EPS (Diluted)	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

TLSA Balance Sheet

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Total Assets	$11.3M-7.4%	$12.2M-54.0%	$26.5M-45.8%	$48.8M-30.9%	$70.7M+2871.2%	$2.4M
Current Assets	$7.5M+2.3%	$7.3M-69.8%	$24.3M-50.1%	$48.7M-30.6%	$70.2M+4562.9%	$1.5M
Cash & Equivalents	$3.7M+214.8%	$1.2M-93.5%	$18.1M-57.0%	$42.2M-35.9%	$65.8M+32812.0%	$200K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$7.3M+10.5%	$6.6M-3.7%	$6.9M-8.5%	$7.5M-8.8%	$8.3M+112.3%	-$67.3M
Current Liabilities	$7.3M+12.4%	$6.5M-1.9%	$6.7M-11.7%	$7.5M-5.4%	$8.0M+8.6%	$7.4M
Long-Term Debt	N/A	$109K-55.1%	$243K	N/A	$290K-46.4%	$541K
Total Equity	$3.9M-28.9%	$5.5M-71.7%	$19.6M-52.6%	$41.3M-33.8%	$62.4M-10.4%	$69.6M
Retained Earnings	-$144.8M-8.3%	-$133.7M-15.0%	-$116.3M-7.6%	-$108.1M-27.7%	-$84.6M-41.0%	-$60.0M

Metric	Q4'24	Q4'23	Q4'22	Q4'21	Q4'20	Q4'19	Q4'18	Q4'17
Total Assets	$11.3M-7.4%	$12.2M-54.0%	$26.5M-45.8%	$48.8M-30.9%	$70.7M+2871.2%	$2.4M-65.6%	$6.9M+180.0%	$2.5M
Current Assets	$7.5M+2.3%	$7.3M-69.8%	$24.3M-50.1%	$48.7M-30.6%	$70.2M+4562.9%	$1.5M-78.2%	$6.9M+182.4%	$2.4M
Cash & Equivalents	$3.7M+214.8%	$1.2M-93.5%	$18.1M-57.0%	$42.2M-35.9%	$65.8M+32812.0%	$200K-96.2%	$5.3M+8187.5%	$64K
Inventory	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Goodwill	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$7.3M+10.5%	$6.6M-3.7%	$6.9M-8.5%	$7.5M-8.8%	$8.3M+112.3%	-$67.3M+2.3%	-$68.8M-1549.7%	$4.7M
Current Liabilities	$7.3M+12.4%	$6.5M-1.9%	$6.7M-11.7%	$7.5M-5.4%	$8.0M+8.6%	$7.4M+14.8%	$6.4M+34.8%	$4.7M
Long-Term Debt	N/A	$109K-55.1%	$243K	N/A	$290K-46.4%	$541K-35.5%	$839K+189.3%	$290K
Total Equity	$3.9M-28.9%	$5.5M-71.7%	$19.6M-52.6%	$41.3M-33.8%	$62.4M-10.4%	$69.6M-8.1%	$75.8M+3426.1%	-$2.3M
Retained Earnings	-$144.8M-8.3%	-$133.7M-15.0%	-$116.3M-7.6%	-$108.1M-27.7%	-$84.6M-41.0%	-$60.0M-18.4%	-$50.7M-19.0%	-$42.6M

TLSA Cash Flow Statement

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Operating Cash Flow	-$1.5M+90.3%	-$15.7M+20.0%	-$19.6M+9.9%	-$21.8M-92.0%	-$11.3M-66.8%	-$6.8M
Capital Expenditures	$19K	N/A	N/A	$22K+633.3%	$3K-25.0%	$4K
Free Cash Flow	-$1.5M	N/A	N/A	-$21.8M-92.1%	-$11.3M-66.7%	-$6.8M
Investing Cash Flow	-$71K+94.3%	-$1.3M+68.6%	-$4.0M-3173.8%	$130K+205.7%	-$123K-2975.0%	-$4K
Financing Cash Flow	$4.5M+11162.5%	$40K+172.7%	-$55K-139.1%	-$23K-100.0%	$75.3M+4384.9%	$1.7M
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'24	Q4'23	Q4'22	Q4'21	Q4'20	Q4'19	Q4'18	Q4'17
Operating Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Capital Expenditures	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Free Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Investing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Financing Cash Flow	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Dividends Paid	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Share Buybacks	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

TLSA Financial Ratios

Metric	FY24	FY23	FY22	FY21	FY20	FY19
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	-301.4%+18.2pp	-319.6%-240.9pp	-78.7%-21.9pp	-56.7%-14.8pp	-41.9%-28.5pp	-13.4%
Return on Assets	-105.1%+40.1pp	-145.2%-87.0pp	-58.1%-10.2pp	-48.0%-11.0pp	-37.0%+355.1pp	-392.1%
Current Ratio	1.02-0.1	1.12-2.5	3.64-2.8	6.45-2.3	8.79+8.6	0.20
Debt-to-Equity	1.87+1.8	0.020.0	0.01-0.2	0.18+0.2	0.000.0	0.01
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q4'24	Q4'23	Q4'22	Q4'21	Q4'20	Q4'19	Q4'18	Q4'17
Gross Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Return on Assets	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Current Ratio	1.02-0.1	1.12-2.5	3.64-2.8	6.45-2.3	8.79+8.6	0.20-0.9	1.08+0.6	0.52
Debt-to-Equity	1.87+1.8	0.020.0	0.01-0.2	0.18+0.2	0.000.0	0.010.0	0.01+0.1	-0.13
FCF Margin	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Similar Companies

Entrada Therapeutics, Inc. TRDA

$503.4M

Sellas Life Sciences Group Inc SLS

$741.7M

Kyverna Therapeutics KYTX

$536.2M

Voyager Therapeutics Inc VYGR

$236.0M

Third Harmonic Bio Inc THRD

$242.8M

Frequently Asked Questions

Is Tiziana Life Sciences Ltd Com profitable?

No, Tiziana Life Sciences Ltd Com (TLSA) reported a net income of -$11.9M in fiscal year 2024.

What is Tiziana Life Sciences Ltd Com's return on equity (ROE)?

Tiziana Life Sciences Ltd Com (TLSA) has a return on equity of -301.4% for fiscal year 2024, measuring how efficiently the company generates profit from shareholder equity.

What is Tiziana Life Sciences Ltd Com's free cash flow?

Tiziana Life Sciences Ltd Com (TLSA) generated -$1.5M in free cash flow during fiscal year 2024. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Tiziana Life Sciences Ltd Com's operating cash flow?

Tiziana Life Sciences Ltd Com (TLSA) generated -$1.5M in operating cash flow during fiscal year 2024, representing cash generated from core business activities.

What are Tiziana Life Sciences Ltd Com's total assets?

Tiziana Life Sciences Ltd Com (TLSA) had $11.3M in total assets as of fiscal year 2024, including both current and long-term assets.

What are Tiziana Life Sciences Ltd Com's capital expenditures?

Tiziana Life Sciences Ltd Com (TLSA) invested $19K in capital expenditures during fiscal year 2024, funding long-term assets and infrastructure.

How many shares does Tiziana Life Sciences Ltd Com have outstanding?

Tiziana Life Sciences Ltd Com (TLSA) had 111M shares outstanding as of fiscal year 2024.

What is Tiziana Life Sciences Ltd Com's current ratio?

Tiziana Life Sciences Ltd Com (TLSA) had a current ratio of 1.02 as of fiscal year 2024, which is considered adequate.

What is Tiziana Life Sciences Ltd Com's debt-to-equity ratio?

Tiziana Life Sciences Ltd Com (TLSA) had a debt-to-equity ratio of 1.87 as of fiscal year 2024, measuring the company's financial leverage by comparing total debt to shareholder equity.

What is Tiziana Life Sciences Ltd Com's return on assets (ROA)?

Tiziana Life Sciences Ltd Com (TLSA) had a return on assets of -105.1% for fiscal year 2024, measuring how efficiently the company uses its assets to generate profit.

What is Tiziana Life Sciences Ltd Com's cash runway?

Based on fiscal year 2024 data, Tiziana Life Sciences Ltd Com (TLSA) had $3.7M in cash against an annual operating cash burn of $1.5M. This gives an estimated cash runway of approximately 29 months at the current burn rate. Cash runway measures how long a company can continue operating before running out of cash, assuming no additional funding.

What is Tiziana Life Sciences Ltd Com's Piotroski F-Score?

Tiziana Life Sciences Ltd Com (TLSA) has a Piotroski F-Score of 3 out of 9, indicating weak financial health. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7–9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Tiziana Life Sciences Ltd Com's earnings high quality?

Tiziana Life Sciences Ltd Com (TLSA) has an earnings quality ratio of 0.13x, considered low quality (accrual-driven). This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.